Manuel Oscar Blanco B.
- Country
- Spain
- Department
- Neuropediatric
Research Overview
- Longterm, openlabel (doseblinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine
- Efficacy and Safety Evaluation of Intravenous Eptinezumab for Preventive Treatment of Chronic Migraine in Adolescents: A Randomized, Double-Blind, Placebo-Controlled Trial
- Evaluation of Rimegepant for Migraine Prophylaxis in Pediatric Patients Aged 6 to <18 Years: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 27 of 73 partner sites.
Specializations
Pediatric Neurology
The investigator specializes in treating neurological disorders in children and adolescents, with particular emphasis on migraine management across different age groups from 6 to 18 years.
- Pediatric migraine treatment
- Adolescent headache disorders
- Age-specific therapeutic approaches
Key focus includes both episodic and chronic migraine conditions in young patients.
Preventive Medicine
Dedicated to developing preventive treatment strategies for pediatric migraine, including evaluation of innovative therapeutic approaches for reducing migraine frequency in young populations.
- Migraine prevention protocols
- Long-term treatment planning
- Preventive intervention assessment
Specializes in evaluating preventive treatments for both episodic and chronic migraine patterns.
Therapeutic Innovation
Focuses on investigating novel therapeutic agents for migraine management in pediatric populations, including assessment of targeted biological treatments.
- Advanced treatment modalities
- Pediatric-specific interventions
- Therapeutic efficacy assessment
Expertise in evaluating new therapeutic options for young patients with various migraine presentations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.